Cue Biopharma, Inc.

NASDAQ:CUE

Biotechnology

Healthcare
$14.10 +1.42%

+$0.38 today

Market cap
$102.43M
Beta
2.53
P/E (TTM)
-6.7
EPS (TTM)
-$4.06
52W Low $4.98High $41.42

Volume 0.21M

Average 0.74M

CUE Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Cue Biopharma, Inc.NASDAQ: CUE

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin holds steady near 100.0%

Gross margin was 100.0% in Q1 FY2026, up 0.0 pp from a year earlier. On a trailing-twelve-month basis it was 99.8%, down 0.2 pp year over year. Over 3 fiscal years it widened by 0.0 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
100.0%+0.0 pp QoQ
Last fiscal yearDec 2025
100.0%+0.0 pp YoY
LTMMar 2026
99.8%-0.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.0 pp——
1 year+0.0 pp——
3 years+0.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+0.0pp

Gross Margin vs competitors

How CUE compares with its peers on the latest reported figures

  • CUE's LTM Mar 2026 gross margin of 99.8% is the highest of the 5 companies compared; the peer median is 62.2%.
  • Its year-over-year change of -0.2 pp is the 2nd highest of 4, against a peer median of -12.0 pp.
  • Over three fiscal years its change of +0.0 pp compares with a peer median of -12.0 pp.
CUE Competitors Peer median
Gross Margin for CUE and competitors
Company Period LTM level YoY 3-year change
CUECue Biopharma, Inc.LTM Mar 202699.8% -0.2 pp+0.0 pp
IPSCCentury Therapeutics, Inc.FY202588.0% -12.0 pp-12.0 pp
COEPCoeptis Therapeutics, Inc.LTM Mar 202687.2% +59.0 pp—
NRXPNRx Pharmaceuticals, Inc.LTM Mar 202637.1% ——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-360.9% -377.1 pp—
SPRBSpruce Biosciences, Inc.FY2025— ——
EQEquillium, Inc.FY2025— ——
Peer median (excluding CUE) 62.2%-12.0 pp-12.0 pp

Competitors are the stored peer set for CUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue14.94M1.25M5.49M9.29M27.47M
Cost of Revenue(1.78M)038.1M00
Gross Profit16.72M1.25M(32.61M)9.29M27.47M
Gross Margin111.9%100.0%-593.9%100.0%100.0%
Research & Development41.35M38.58M40.8M36.3M37.74M
Selling, General & Admin17.31M16.17M16.68M14.59M16.24M
Operating Expenses60.43M54.47M19.54M50.79M53.99M
Depreciation & Amortization(1.78M)1.81M3.44M2.35M3.48M
EBITDA(45.44M)(50.49M)(46.05M)(37.53M)(22.27M)
EBITDA Margin-304.1%-4055.5%-838.8%-404.1%-81.1%
Operating Income(43.71M)(53.23M)(52.15M)(41.5M)(26.52M)
Operating Margin-292.6%-4275.1%-949.9%-446.9%-96.6%
Interest Income45.9K928.24K2.66M1.62M807K
Interest Expense0713.82K1.25M796K357K
Other Income / Expenses45.9K215K1.42M826K419K
Income Before Tax(43.67M)(53.01M)(50.73M)(40.67M)(26.1M)
Pre-Tax Margin-292.3%-4257.8%-924.1%-438.0%-95.0%
Income Tax Expense495K000500K
Net Income(44.16M)(53.01M)(50.73M)(40.67M)(26.6M)
Net Margin-295.6%-4257.8%-924.1%-438.0%-96.9%
EPS (Basic)(42.30)(44.70)(33.30)(21.60)(8.40)
EPS (Diluted)(42.30)(44.70)(33.30)(21.60)(8.40)
Weighted Avg Shares1.04M1.19M1.53M1.88M3.16M
Weighted Avg Shares (Diluted)1.04M1.19M1.53M1.88M3.16M

Cue Biopharma, Inc.

NASDAQ:CUE

Intrinsic Alpha fair value

Locked

Current Price

$14.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.